NO20081427L - Alfa2c-adrenoreseptoragonister - Google Patents
Alfa2c-adrenoreseptoragonisterInfo
- Publication number
- NO20081427L NO20081427L NO20081427A NO20081427A NO20081427L NO 20081427 L NO20081427 L NO 20081427L NO 20081427 A NO20081427 A NO 20081427A NO 20081427 A NO20081427 A NO 20081427A NO 20081427 L NO20081427 L NO 20081427L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- alpha2c
- agonists
- adrenoreceptor agonists
- adrenergic receptor
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 102100025983 Alpha-2C adrenergic receptor Human genes 0.000 title 1
- 101710149275 Alpha-2C adrenergic receptor Proteins 0.000 title 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 abstract 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- FHQRDEDZJIFJAL-UHFFFAOYSA-N 4-phenylmorpholine Chemical class C1COCCN1C1=CC=CC=C1 FHQRDEDZJIFJAL-UHFFFAOYSA-N 0.000 abstract 1
- DPXANBQAIVUQDO-UHFFFAOYSA-N 4-phenylthiomorpholine Chemical class C1CSCCN1C1=CC=CC=C1 DPXANBQAIVUQDO-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71145305P | 2005-08-25 | 2005-08-25 | |
| PCT/US2006/032917 WO2007024949A2 (en) | 2005-08-25 | 2006-08-23 | Alpha2c adrenoreceptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20081427L true NO20081427L (no) | 2008-05-23 |
Family
ID=37668030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20081427A NO20081427L (no) | 2005-08-25 | 2008-03-18 | Alfa2c-adrenoreseptoragonister |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20070093477A1 (de) |
| EP (1) | EP1934203B1 (de) |
| JP (2) | JP2009506051A (de) |
| KR (1) | KR20080037070A (de) |
| CN (1) | CN101374830A (de) |
| AR (1) | AR057771A1 (de) |
| AT (1) | ATE478069T1 (de) |
| AU (1) | AU2006283109A1 (de) |
| BR (1) | BRPI0615021A2 (de) |
| CA (1) | CA2620173A1 (de) |
| DE (1) | DE602006016303D1 (de) |
| EC (1) | ECSP088221A (de) |
| ES (1) | ES2348997T3 (de) |
| IL (1) | IL189678A0 (de) |
| NO (1) | NO20081427L (de) |
| PE (1) | PE20070519A1 (de) |
| RU (1) | RU2008110902A (de) |
| SG (1) | SG165315A1 (de) |
| TW (1) | TWI329643B (de) |
| WO (1) | WO2007024949A2 (de) |
| ZA (1) | ZA200802495B (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2348997T3 (es) | 2005-08-25 | 2010-12-21 | Schering Corporation | Compuestos de 3,4-dihidro-2h-benzo[1,4]oxazina y 3,4-dihidro-2h-benzo[1,4]tiazina como agonistas del adrenorreceptor alfa2c. |
| US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
| JP5099814B2 (ja) * | 2006-02-02 | 2012-12-19 | 田辺三菱製薬株式会社 | 含窒素複素二環式化合物 |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| AU2007316257A1 (en) | 2006-11-02 | 2008-05-08 | F. Hoffmann-La Roche Ag | Substituted 2-imidazoles as modulators of the trace amine associated receptors |
| WO2008058867A2 (en) * | 2006-11-16 | 2008-05-22 | F. Hoffmann-La Roche Ag | Substituted 4-imidazoles |
| BRPI0807961A2 (pt) * | 2007-02-13 | 2017-05-16 | Pharmacopeia Llc | agonista de alfa2c adrenorreceptor funcionalmente seletivos. |
| CA2678069A1 (en) * | 2007-02-13 | 2008-08-21 | Schering Corporation | Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| EP2398776A1 (de) * | 2007-02-13 | 2011-12-28 | Schering Corporation | Funktional selektive alpha2c-adrenorezeptor-agonisten |
| WO2009035997A2 (en) | 2007-09-14 | 2009-03-19 | Cara Therapeutics, Inc. | Benzo-fused heterocycles |
| UA105182C2 (ru) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность |
| EP2323734A1 (de) * | 2008-08-04 | 2011-05-25 | Schering Corporation | Cyclopropylchromen-derivate als modulatoren des alpha-2c-rezeptors |
| US20110172217A1 (en) * | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| EP2344491A2 (de) * | 2008-09-16 | 2011-07-20 | Schering Corporation | Funktionell selektive azanitrile als agonisten des alpha2c-adrenozeptors |
| TW201026688A (en) * | 2008-10-07 | 2010-07-16 | Schering Corp | Benzodioxan analogues as alpha2C adrenergic receptor modulators |
| TW201026691A (en) | 2008-10-07 | 2010-07-16 | Schering Corp | Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators |
| EP2430011A1 (de) | 2009-05-15 | 2012-03-21 | Novartis AG | 5-pyridin-3-yl-1,3-dihydro-indol-2-on-derivate und ihre verwendung als aldosteronsynthase- und/oder cyp11b1-modulatoren |
| JP5654572B2 (ja) * | 2009-05-15 | 2015-01-14 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体 |
| EA201290007A1 (ru) * | 2009-08-10 | 2013-01-30 | Беллус Хелс Инк. | Способы, соединения и композиции для доставки 1,3-пропандисульфокислоты |
| WO2012075115A1 (en) * | 2010-12-01 | 2012-06-07 | Janssen Pharmaceutica Nv | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2 |
| US20140315881A1 (en) * | 2011-07-29 | 2014-10-23 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| US9195953B2 (en) * | 2011-08-16 | 2015-11-24 | Walk Score Management LLC | System and method for the calculation and use of travel times in search and other applications |
| WO2013076590A1 (en) * | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
| CN103588722A (zh) * | 2012-08-17 | 2014-02-19 | 苏州中科天马肽工程中心有限公司 | 6-硝基-2h-1,4-苯并恶嗪-3(4h)-酮的合成方法 |
| KR20200131246A (ko) | 2018-02-15 | 2020-11-23 | 누베이션 바이오 인크. | 키나제 억제제로서의 헤테로시클릭 화합물 |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| BR112022002532A2 (pt) * | 2019-08-14 | 2022-07-19 | Nuvation Bio Inc | Compostos heterocíclicos como inibidores de quinase |
| CN115151304B (zh) * | 2020-02-12 | 2025-02-11 | 库拉德夫制药私人有限公司 | 小分子干扰素基因刺激因子(sting)拮抗剂 |
| IL317578A (en) * | 2022-06-10 | 2025-02-01 | Sapiensbio Inc | A new compound, and a pharmaceutical composition consisting of the same active ingredient |
| WO2024025896A2 (en) * | 2022-07-25 | 2024-02-01 | Evommune, Inc. | Protein kinase c (pkc) theta inhibitor compounds |
| WO2025099111A1 (en) | 2023-11-10 | 2025-05-15 | Wella Germany Gmbh | New telescoping syntheses of 6-hydroxy-benzomorpholine (3,4-dihydro-2h-1,4-benzoxazin-6-ol) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US5856106A (en) * | 1995-11-01 | 1999-01-05 | Biotransplant, Inc. | Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| BR9813381A (pt) * | 1997-12-04 | 2000-10-03 | Allergan Sales Inc | "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" |
| US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| JP4927298B2 (ja) * | 2000-07-14 | 2012-05-09 | アラーガン、インコーポレイテッド | α−２−アドレナリンアゴニスト成分を含有する組成物 |
| US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| FI20022159A0 (fi) | 2002-12-05 | 2002-12-05 | Orion Corp | Uusia farmaseuttisia yhdisteitä |
| WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| CA2581828A1 (en) * | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| US7700592B2 (en) * | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
| ES2348997T3 (es) | 2005-08-25 | 2010-12-21 | Schering Corporation | Compuestos de 3,4-dihidro-2h-benzo[1,4]oxazina y 3,4-dihidro-2h-benzo[1,4]tiazina como agonistas del adrenorreceptor alfa2c. |
-
2006
- 2006-08-23 ES ES06802156T patent/ES2348997T3/es active Active
- 2006-08-23 EP EP06802156A patent/EP1934203B1/de active Active
- 2006-08-23 BR BRPI0615021-7A patent/BRPI0615021A2/pt not_active IP Right Cessation
- 2006-08-23 SG SG201006198-4A patent/SG165315A1/en unknown
- 2006-08-23 CN CNA2006800397664A patent/CN101374830A/zh active Pending
- 2006-08-23 PE PE2006001024A patent/PE20070519A1/es not_active Application Discontinuation
- 2006-08-23 JP JP2008528110A patent/JP2009506051A/ja active Pending
- 2006-08-23 DE DE602006016303T patent/DE602006016303D1/de active Active
- 2006-08-23 CA CA002620173A patent/CA2620173A1/en not_active Abandoned
- 2006-08-23 KR KR1020087005570A patent/KR20080037070A/ko not_active Withdrawn
- 2006-08-23 AT AT06802156T patent/ATE478069T1/de not_active IP Right Cessation
- 2006-08-23 US US11/508,467 patent/US20070093477A1/en not_active Abandoned
- 2006-08-23 RU RU2008110902/04A patent/RU2008110902A/ru not_active Application Discontinuation
- 2006-08-23 WO PCT/US2006/032917 patent/WO2007024949A2/en not_active Ceased
- 2006-08-23 AR ARP060103662A patent/AR057771A1/es not_active Application Discontinuation
- 2006-08-23 AU AU2006283109A patent/AU2006283109A1/en not_active Abandoned
- 2006-08-24 TW TW095131073A patent/TWI329643B/zh active
-
2008
- 2008-02-21 IL IL189678A patent/IL189678A0/en unknown
- 2008-02-25 EC EC2008008221A patent/ECSP088221A/es unknown
- 2008-03-18 NO NO20081427A patent/NO20081427L/no not_active Application Discontinuation
- 2008-03-18 ZA ZA200802495A patent/ZA200802495B/xx unknown
- 2008-05-22 JP JP2008134858A patent/JP2009185016A/ja active Pending
-
2010
- 2010-03-12 US US12/722,879 patent/US7985748B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009506051A (ja) | 2009-02-12 |
| ZA200802495B (en) | 2008-12-31 |
| DE602006016303D1 (de) | 2010-09-30 |
| CN101374830A (zh) | 2009-02-25 |
| CA2620173A1 (en) | 2007-03-01 |
| RU2008110902A (ru) | 2009-09-27 |
| EP1934203B1 (de) | 2010-08-18 |
| PE20070519A1 (es) | 2007-07-13 |
| IL189678A0 (en) | 2008-08-07 |
| WO2007024949A3 (en) | 2007-06-07 |
| AR057771A1 (es) | 2007-12-19 |
| EP1934203A2 (de) | 2008-06-25 |
| TW200740799A (en) | 2007-11-01 |
| AU2006283109A1 (en) | 2007-03-01 |
| JP2009185016A (ja) | 2009-08-20 |
| US20070093477A1 (en) | 2007-04-26 |
| US20100173823A1 (en) | 2010-07-08 |
| BRPI0615021A2 (pt) | 2011-04-26 |
| US7985748B2 (en) | 2011-07-26 |
| ATE478069T1 (de) | 2010-09-15 |
| KR20080037070A (ko) | 2008-04-29 |
| ES2348997T3 (es) | 2010-12-21 |
| TWI329643B (en) | 2010-09-01 |
| ECSP088221A (es) | 2008-03-26 |
| HK1118812A1 (en) | 2009-02-20 |
| SG165315A1 (en) | 2010-10-28 |
| WO2007024949A2 (en) | 2007-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20081426L (no) | Imidazolderivater som funksjonelt selektive alfa2c-adrenoreseptoragonister | |
| TW200740799A (en) | Alpha2C adrenoreceptor agonists | |
| EA202092580A1 (ru) | Соединения, ингибирующие rip1, а также способы их получения и применения | |
| NO20082673L (no) | Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens | |
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| MX2020014098A (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington. | |
| MX2020009956A (es) | Compuestos para el tratamiento de enfermedad de hungtinton. | |
| NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser | |
| NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
| NO20091326L (no) | Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase | |
| WO2017100726A8 (en) | Methods for treating huntington's disease | |
| NO20082091L (no) | Nye pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer | |
| UA103319C2 (en) | Thiazole- and oxazole-benzene sulfonamide compounds | |
| MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
| NO20082092L (no) | Pyrazolopyrimidiner som proteinkinaseinhibitorer | |
| NO20092130L (no) | Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase | |
| NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
| NO20082530L (no) | Imidazopyraziner som proteinkinaseinhibitorer | |
| EA201071291A3 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| IL200793A0 (en) | Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases | |
| UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
| NO20084924L (no) | N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer | |
| MA38393B1 (fr) | Composés hétéroaryle et utilisations associées | |
| MX2009006345A (es) | Compuestos utiles como inhibidores de proteina cinasa. | |
| NO20084850L (no) | MGLUR5 modulatorer I |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |